The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

New England Journal of Medicine

Volumn 338, Issue 20, 1998, Pages 1405-1412

  Belshe, Robert B ^a,l   Mendelman, Paul M ^b   Treanor, John ^c   King, James ^d   Gruber, William C ^e   Piedra, Pedro ^f   Bernstein, David I ^g   Hayden, Frederick G ^h   Kotloff, Karen ^d   Zangwill, Ken ⁱ   Iacuzio, Dominick ^j   Wolff, Mark ^k   Reisinger, Keith ^m   Block, Stan L ⁿ   Wittes, Janet ^o   Rabinovich, Regina ^j  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDIMMUNE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ HARBOR UCLA MEDICAL CENTER   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k EMMES CORPORATION   (United States)

^l S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^m NIOSH Pittsburgh Research Laboratory   (United States)

ⁿ Kentucky Pediatric Research Institute   (United States)

^o University of Iowa   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOGENICITY; INFLUENZA; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SEROLOGY; VIRUS CULTURE;

ADMINISTRATION, INTRANASAL; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; FEVER; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; OTITIS MEDIA; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VACCINES, ATTENUATED;

EID: 0032516267     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199805143382002     Document Type: Article

References (31)

1. Glezen WP, Paredes A, Taber LH. Influenza in children: relationship to other respiratory agents. JAMA 1980;243:1345-9.
2. Wright PF, Thompson T, Karzon DT. Differing virulence of H1N1 and H3N2 influenza strains. Am J Epidemiol 1980;112:814-9.
3. Fox JP, Cooney MK, Hall CE, Foy HM. Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol 1982;116:228-42.
4. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46(RR-9):1-25.
5. Maassab HF, Heilman CA, Herlocher ML. Cold-adapted influenza viruses for use as live vaccines for man. Adv Biotechnol Processes 1990;14: 203-42.
6. Couch RB. Advances in influenza virus vaccine research. Ann N Y Acad Sci 1993;685:803-12.
7. Clancy RL. Mucosal vaccines for the prevention of influenza. Drugs 1995;50:587-94.
8. Belshe RB. A review of attenuation of influenza viruses by genetic manipulation. Am J Respir Crit Care Med 1995;152:S72-S75.
9. Maassab HF. Biologic and immunologic characteristics of cold-adapted influenza virus. J Immunol 1969;102:728-32.
10. Cox NJ, Maassab HF, Kendal AP. Comparative studies of wild-type and cold-mutant (temperature-sensitive) influenza viruses: nonrandom reassortment of genes during preparation of live virus vaccine candidates by recombination at 25° between recent H3N2 and H1N1 epidemic strains and cold-adapted A/Ann Arbor/6/60. Virology 1979;97:190-4.
11. Maassab HF, DeBorde DC. Characterization of an influenza A host range mutant. Virology 1983;130:342-50.
12. Maassab HF, Kendal AP, Abrams GD, Monto AS. Evaluation of a cold-recombinant influenza virus vaccine in ferrets. J Infect Dis 1982;146:780-90.
13. Donabedian AM, DeBorde DC, Maassab HF. Genetics of cold-adapted B/Ann Arbor/1/66 influenza virus reassortants: the acidic polymerase (PA) protein gene confers temperature sensitivity and attenuated virulence. Microb Pathog 1987;3:97-108.
14. The 1995-96 WHO influenza reagent kit for the identification of influenza isolates. Appendix A. Atlanta: Centers for Disease Control and Prevention, 1995.
15. COSTART: coding symbols for thesaurus of adverse reaction terms. 5th ed. Rockville, Md.: Food and Drug Administration, 1995.
16. SAS, version 6.12. Cary, N.C.: SAS Institute, 1996 (software).
17. StatXact 3 for Windows. Cambridge, Mass.: Cytel Software, 1995 (software).
18. Swierkosz EM, Newman FK, Anderson EL, Nugent SL, Mills GB, Belshe RB. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children. J Infect Dis 1994;169:1121-4.
19. Gruber WC, Belshe RB, King JC, et al. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. J Infect Dis 1996;173:1313-9.
20. Powers DC, Sears SD, Murphy BR, Thumar B, Clements ML. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J Clin Microbiol 1989;27:2666-71.
21. Gorse GF, Belshe RB, Munn NJ. Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines. J Clin Microbiol 1988;26:911-8.
22. Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986;23:66-72.
23. Wright PF, Karzon DT. Live attenuated influenza vaccines. Prog Med Virol 1987;34:70-88.
24. Johnson PR, Feldman S, Thompson JM, Mahoney JD, Wright PF. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 1986;154:121-7.
25. Moldoveanu Z, Clements ML, Prince SJ, Murphy BR, Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 1995;13:1006-12.
26. Sugaya N, Nerome K, Ishida M, Matsumoto M, Mitamura K, Nirasawa M. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA 1994;272:1122-6.
27. Chonmaitree T, Howie VM, Truant AL. Presence of respiratory viruses in middle ear fluids and nasal wash specimens from children with acute otitis media. Pediatrics 1986;77:698-702.
28. Chonmaitree T, Owen MJ, Howie VM. Respiratory viruses interfere with bacteriologic response to antibiotic in children with acute otitis media. J Infect Dis 1990;162:546-9.
29. Chonmaitree T, Owen MJ, Patel JA, Hedgpeth D, Horlick D, Howie VM. Effect of viral respiratory tract infection on outcome of acute otitis media. J Pediatr 1992;120:856-62.
30. Chonmaitrce T, Patel JA, Lett-Brown MA, et al. Virus and bacteria enhance histamine production in middle ear fluids of children with acute otitis media. J Infect Dis 1994;169:1265-70.
31. Clements DA, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6-to 30-month-old children in day care. Arch Pediatr Adolesc Med 1995;149:1113-7.